Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus

NCT02106897 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

109

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus
Healthy Volunteers

Interventions

DRUG: BIIB059 (litifilimab)
DRUG: Placebo

Sponsor

Biogen